233 related articles for article (PubMed ID: 33292612)
1. The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial.
Feldt M; Menard J; Rosendahl AH; Lettiero B; Bendahl PO; Belting M; Borgquist S
Cancer Metab; 2020 Nov; 8(1):25. PubMed ID: 33292612
[TBL] [Abstract][Full Text] [Related]
2. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
Feldt M; Bjarnadottir O; Kimbung S; Jirström K; Bendahl PO; Veerla S; Grabau D; Hedenfalk I; Borgquist S
J Transl Med; 2015 Apr; 13():133. PubMed ID: 25925673
[TBL] [Abstract][Full Text] [Related]
3. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
4. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
[TBL] [Abstract][Full Text] [Related]
5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Pocathikorn A; Taylor RR; Mamotte CD
Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):471-6. PubMed ID: 19930424
[TBL] [Abstract][Full Text] [Related]
7. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins.
Furuya Y; Sekine Y; Kato H; Miyazawa Y; Koike H; Suzuki K
Prostate Int; 2016 Jun; 4(2):56-60. PubMed ID: 27358845
[TBL] [Abstract][Full Text] [Related]
9. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
10. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids.
Zimmermann F; Roessler J; Schmidt D; Jasina A; Schumann P; Gast M; Poller W; Leistner D; Giral H; Kränkel N; Kratzer A; Schuchardt S; Heimesaat MM; Landmesser U; Haghikia A
J Clin Med; 2020 May; 9(5):. PubMed ID: 32466086
[TBL] [Abstract][Full Text] [Related]
12. Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia.
Gallagher EJ; Zelenko Z; Neel BA; Antoniou IM; Rajan L; Kase N; LeRoith D
Oncogene; 2017 Nov; 36(46):6462-6471. PubMed ID: 28759039
[TBL] [Abstract][Full Text] [Related]
13. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Watts GF; Chan DC; Dent R; Somaratne R; Wasserman SM; Scott R; Burrows S; R Barrett PH
Circulation; 2017 Jan; 135(4):338-351. PubMed ID: 27941065
[TBL] [Abstract][Full Text] [Related]
14. Impact of LDLR polymorphisms on lipid levels and atorvastatin's efficacy in a northern Chinese adult Han cohort with dyslipidemia.
Zhao HL; You Y; Tian Y; Wang L; An Y; Zhang G; Shu C; Yu M; Zhu Y; Li Q; Zhang Y; Sun N; Hu S; Liu G
Lipids Health Dis; 2024 Apr; 23(1):106. PubMed ID: 38616260
[TBL] [Abstract][Full Text] [Related]
15. RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol.
Mitchel K; Theusch E; Cubitt C; Dosé AC; Stevens K; Naidoo D; Medina MW
Circ Cardiovasc Genet; 2016 Jun; 9(3):223-30. PubMed ID: 27071970
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.
Soran H; Liu Y; Adam S; Siahmansur T; Ho JH; Schofield JD; Kwok S; Gittins M; France M; Younis N; Gibson JM; Durrington PN; Rutter MK
J Clin Lipidol; 2018; 12(1):44-55. PubMed ID: 29246729
[TBL] [Abstract][Full Text] [Related]
18. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
